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Background: Studies of primary patient tumor xenografts grown in immunodeficient mice have shown that these
tumors histologically and genetically closely resemble the original tumors. These patient xenograft models are
becoming widely used for therapeutic efficacy studies. Because many therapies are directed at tumor stromal
components and because the tumor microenvironment also is known to influence the response of a tumor to
therapy, it is important to understand the nature of the stroma and, in particular, the vascular supply of patient
xenografts.
Methods: Patient tumor xenografts were established by implanting undisrupted pieces of patient tumors in SCID
mice. For this study, formalin fixed, paraffin embedded specimens from several types of solid tumors were selected
and, using species-specific antibodies which react with formalin fixed antigens, we analyzed the species origin of the
stroma and blood vessels that supported tumor growth in these models. Additionally, we investigated the kinetics of
the vascularization process in a colon tumor and a mesothelioma xenograft. In mice bearing a head and neck
xenograft, a perfusion study was performed to compare the functionality of the human and mouse tumor vessels.
Results: In patient tumors which successfully engrafted, the human stroma and vessels which were engrafted as part
of the original tumor did not survive and were no longer detectable at the time of first passage (15–25 weeks).
Uniformly, the stroma and vessels supporting the growth of these tumors were of murine origin. The results of the
kinetic studies showed that the loss of the human vessels and vascularization by host vessels occurred more rapidly in
a colon tumor (by 3 weeks) than in a mesothelioma (by 9 weeks). Finally, the perfusion studies revealed that while
mouse vessels in the periphery of the tumor were perfused, those in the central regions were rarely perfused. No
vessels of human origin were detected in this model.
Conclusions: In the tumors we investigated, we found no evidence that the human stromal cells and vessels
contained in the original implant either survived or contributed in any substantive way to the growth of these
xenografts.
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Pre-clinical investigations of therapeutics for treatment
of malignant disease are most often carried out using
mouse models. Human tumor xenograft models have
traditionally utilized established cell lines, but more
recently, engraftment of undisrupted, intact pieces of
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reproduction in any medium, provided the orresemble the histological organization of patient tumors
[1-9]. The maintenance of the architecture of the
original patient tumor in combination with the presence
of low passage tumor cells results in a model which is
highly representative of the diversity of tumors seen in
the patient population and, therefore, the benefit of
using this model for therapeutic studies is becoming
more widely appreciated (e.g. [10]). Recent reports es-
tablish two important facts: 1) that primary xenografts
genetically resemble the original tumor through severalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remain genetically representative of the original [11,12].
In light of the recognized importance of the tumor
microenvironment in tumor growth and sensitivity to a
variety of treatments, critical issues associated with
patient-derived xenografts include determining which
components of the original specimen survive and proli-
ferate and which components of the xenografted tumor
are derived from the host. Data supporting the presence
of host derived components was reported recently by
Lin et al. [13]. In this study 43% of the patient pancreatic
tumor xenografts analyzed had greater than 50% mouse
DNA, indicating that a significant component of the
xenograft is derived from the host. In the case of human
cell lines, it has been reported that the vessels are of
murine origin [14] and the stroma is recruited and
derived from the host [15]. However, there are also
reports of “mosaic” vessels partially lined by human
tumor cells [16] and “vascular mimicry” in which blood
cells are seen in channels lined by tumor cells, not endo-
thelial cells [17,18] as well as actual transdifferentiation
of tumor cells into cells that are positive for endothelial
cell markers in glioblastoma models [19]. In primary
tumor xenografts derived from intact pieces of patient
tumors, there have been comparatively fewer studies
directly addressing the fate of the stromal elements of
the original graft or the origin of the stromal elements
that support growth of the successful xenografts. A
recent review [20] points out that this issue is still
controversial and unresolved. In our earlier work [21]
describing patient ovarian tumor xenografts, we labeled
sections of ovarian tumors for the ALU element of
human DNA and demonstrated that although tumor
cells were labeled, stromal cells were not, indicating that
the stroma of these successful xenografts was murine.
Recently, two studies have specifically addressed the
question of fate of the human vasculature in the im-
planted specimens with somewhat different conclusions.
Gray et al. [22] studied prostate and renal cell carcinoma
(RCC) xenografts. Xenografts were recovered at 30 days
and analyzed using antibodies with species-specificity to
endothelial cell markers; these authors concluded that in
prostate tumors implanted subcutaneously in nude mice,
human endothelial cells survive and undergo angioge-
nesis such that the majority of the proliferating endothe-
lial cells (80%) are of human origin. This was not the
case for RCC and these authors conclude there may be
differences between tumor types. Sanz et al. [23]
performed a similar study on colorectal cancer xeno-
grafts and found that in contrast to the results reported
for prostate, the human vasculature rapidly disappeared
from growing colorectal xenografts so that by day 10,
50% of the vasculature was murine, by day 20 it was
predominantly murine and by day 30, no human vesselswere detectable. During this time the tumors grew from
approximately 4 mm3 to 250 mm3. More recently, Julien
et al. [5] have carried out an extensive characterization
of a large cohort of patient colon tumor xenografts and
also reported a loss of human stromal cells in early
passages of these xenografts as evidenced by in situ
hybridization with an ALU probe. In agreement with the
earlier report, Sanz et al. also found that at 30 days,
RCC xenografts contained primarily human vessels,
although they did not report the degree of tumor growth
achieved during this period. Merk et al. [24], state that
in non-small cell lung cancer patient xenografts, the
stromal elements are replaced with murine fibroblasts,
endothelial and immune cells. Monsma et al. [11] report
that the stromal elements persist in xenografts, however,
the origin of these elements in engrafted tumors is not
specifically addressed. Therefore, it may be that the fate
of the human vessels is related to individual tumor types
and the timepoint at which the engrafted specimens are
examined.
We undertook the current study to directly address
the question of the origin of the stromal elements in
several different types of xenografted patient tumors
with particular attention to the vasculature and identifi-
cation of the origin of the vessels that support the actual
growth of these xenografts. In representative xenografts of
eight different tumor types, we found that as the tumors
grew to a size to be passaged (approximately 1–1.5 cm
diameter), the stroma which developed was not of human
origin. Furthermore, in a survey of lung, pancreatic, colo-
rectal and renal cell carcinoma, we found uniformly that
the vasculature lacked markers for human endothelial
cells and only vessels of murine origin could be identified.
Our results support the conclusion that successful
engraftment and growth of these patient tumor xenografts
depends on recruitment of stroma and new vessels from
the murine host. Additionally, we examined the kinetics of
vessel recruitment in a colorectal tumor and a mesotheli-
oma and observed that during the initial engraftment,
although the time-frame is slightly different, murine ves-
sels gradually became predominant in both tumors. Lastly,
we found that in an engrafted head and neck tumor,
human vessels were not detected and perfused vessels
were of murine origin. Overall, in the tumors we investi-
gated, we found no evidence that the human stromal cells
and vessels contained in the original implant either
survived or contributed in any substantive way to the
growth of these xenografts.
Methods
Xenograft model
Fresh surgical specimens of tumors were obtained
through the Pathology Resource Network at Roswell Park
Cancer Institute through an approved IRB (Institutional
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37 patient tumors whose xenografts were used for various
aspects of this study are included in Table 1. Of the 37 pa-
tients from whom tumor samples were procured, 9 had
received therapy prior to surgery. All specimens were ex-
amined by a pathologist and confirmed to contain at least
75% malignant tissue; specimens were transported to our
lab and implanted immediately. Tumor specimens were
cut into 2×2 mm pieces and surgically implanted subcuta-
neously in the lower abdomen of 4–6 week old SCID mice
as previously described [4,7]. In general, each patient
tumor was implanted into 2–3 mice and mice were
monitored for tumor growth. Implanted tumors were
recovered and passaged into new mice when tumors
reached approximately 1–1.5 cm in diameter. Tumors
which grew in the second passage were considered suc-
cessfully engrafted. Pieces of tumors recovered during
passaging were formalin fixed, processed for histology and
archived. Mice were maintained under sterile conditions
in microisolator cages; temperature and light cycles were
regulated on a 12 hr. cycle. Mice were fed and had access
to water ad libitum. All manipulations were carried out
aseptically in a laminar flow hood. The RPCI Institutional
Animal Care and Use Committee approved all procedures
carried out in this study. To monitor development of
vasculature during the engraftment process, pieces of a
single patient’s tumor were implanted into a group of
12–15 SCID mice. Periodically, mice were removed from
this group and tumors were fixed and processed for
routine histology. In some cases, tumors were embedded
in OCT for cryosectioning.
Immunohistochemistry
Immunohistochemistry on archival specimens of patient
tumors and xenografts derived from those tumors was
performed on 5 μ sections of formalin-fixed paraffin em-
bedded tissues (FFPE). Since larger tumors often con-
tained scattered areas of central necrosis, all evaluation of
staining was done on selected areas of viable tumor. For
performing IHC on FFPE archival specimens, we selected
and validated the species-specificity of the following anti-
bodies on FFPE tissue. For identification of vessels of
mouse origin, monoclonal rat anti-mouse CD34 was used
(AbCam #8158, clone MEC 14.7) with no pretreatment;
the secondary antibody was biotinylated goat anti-rat
(Pharmingen #554014), and was visualized with either
strepavidin (Zymed) or Vector ABC Elite and diami-
nobenzidine (DAB). For identification of vessels of human
origin, polyclonal rabbit anti-human CD31 (Novus Biolo-
gicals NB100-2284) was used following antigen retrieval
with citrate buffer pH 6.0 (microwave heating 10′ 10%
power, followed by a 15′ cooldown); the DAKO Envision
kit for Rabbit antibodies was used to visualize bound anti-
body. Mouse anti-human CD34 (Abcam #ab8536, cloneQBEND/10, no antigen retrieval) followed by biotinylated
goat anti- mouse secondary (Jackson Immunoresearch
#115-065-062) was also used in some experiments.
Monoclonal mouse anti-human mitochondria antibody
(MAB1273 Chemicon) following antigen retrieval (with
EDTA buffer pH 8.0) was used for identification of cells of
human origin.
For visualization of perfused vessels, a cohort of mice
was engrafted as described above with pieces of a freshly
obtained head and neck tumor [9]. Tumor growth was
monitored and mice were selected at various times post-
engraftment and injected systemically (slowly via tail
vein) with 100 μl Dylite 594 conjugated tomato lectin
(Lycopersicon Esculentum, Vector). After 2–3 minutes,
tumors and intestinal tissue were removed and embe-
dded in OCT. 15-20 μ cryosections were mounted in
Vectastain with DAPI. To identify vessels, sections from
lectin perfused tissue were counterstained. The following
antibodies were used for immunofluorescence: monoclo-
nal mouse anti-human CD34 (Abcam #ab8536, clone
QBEND/10) followed by Dylite 488 conjugated Jackson
biotinylated goat anti-mouse (Jackson Immunoresearch
Cat# 115-485-003) and rat anti-mouse CD31 (Pharmingen
Cat# 01951D) followed by Dylite 488 conjugated goat
anti-rat (Jackson Immunoresearch Cat# 112-485-167).
Analysis of blood vessel density
Stained sections were examined under low magnification
for representative areas of the tumor. At 20× magnifica-
tion, five fields were then selected randomly within these
areas, vessels were counted and the counts averaged to
determine the MVD of either huCD31(+) or msCD34(+)
vessels.
Results
Stromal elements of successfully engrafted patient
tumors do not label for human markers
We were interested in characterizing the process of
engraftment and in delineating which components of the
microenvironment are derived from the implanted
human tumor tissue and which are derived from the
murine host. In order to characterize the origin of the
diverse stromal cells and the vasculature within several
types of patient tumor xenografts using formalin fixed
archival tissue, species-specific antibodies were identified
and immunohistochemical protocols were developed
using FFPE specimens known to contain only human
vasculature (patient surgical specimens) or only mouse
vasculature (xenograft tumors derived from cell lines).
As seen in Figure 1, an antibody specific for a human
mitochondrial antigen labeled both tumor cells and
stromal cells in a patient specimen of colon carcinoma
(Figure 1A) but only the tumor cells in a Colo205
human colon tumor cell line xenograft (Figure 1B). An
Table 1 Clinical characteristics of tumors and experiments in which corresponding xenografts were used
Primary site
description
ID# Exp Sex Age Histology
description
Grade Path T Path N Path M AJCC
stage path
Treatment prior to sample
Esophagus, lower third 12944 2 M 70 Ad, NOS III 2 1 0 2B no
Esophagus, lower third 13176 2 M 40 Ad, NOS III 1 1 1 4 no
Ovary 13575 2 F 67 PSC III 3C 0 0 3C Carboplatin/Taxol
Esophagus 13618 2 nd nd nd nd nd nd nd nd nd
Ovary 13987 2 F 43 SSPC III 3C 1 0 3C no
Pleura, NOS 14967 4 M 70 Meso nd 3 0 0 3 Radiation and chemotherapy
(Alimta & cisplatin)
Pancreas, head of 15010 3 F 74 Inf Duct, NOS II 3 1 0 2B no
Pancreas, body of 15406 3 M 74 Inf Duct, NOS II 2 0 0 1B no
Kidney, NOS 15773 3 M 69 RCC, NOS III 3A 0 1 4 no
Kidney, NOS 15818 3 F 57 RCC, Clear cell III 1B 0 X 1 no
Lung, upper lobe 15946 3 F 73 SCC, NOS III 2 0 0 1B no
Pancreas, tail of 16096 3 M 66 Inf Duct, NOS II 2 0 0 1B no
Colon, ascending 16115 3 M 59 Ad, NOS II X X nd nd FOLFOX with Avastin
Kidney, NOS 16616 3 M 62 RCC, NOS III 3B 0 0 3 no
Kidney, NOS 16692 2, 3 M 57 RCC,
sarcomatoid
IV 3B 1 X 4 no
Kidney, NOS 16803 3 M 63 RCC, Clear cell III 1A X X 1 no
Colon, ascending 16811 3 F 83 Ad, NOS II 4 0 0 2B no
Pancreas, head of 16870 3 F 31 Inf Duct, NOS III 3 1 0 2B no
Colon, Sigmoid, NOS 16879 3 F 76 Ad, NOS II 3 0 0 2A no
Pancreas, head of 17123 3 M 79 Ad, NOS III 3 1 0 2B no
Rectosigmoid junction 17224 2 F 52 Ad, NOS II 3 1 1 4 no
Lung, lower lobe 17228 3 F 82 CSC III 2 0 0 1B no
Colon, ascending 17239 2 M 71 Ad, NOS II 3 2 0 3C no
Lung, upper lobe 17246 2, 3 M 53 Ad, NOS III 3 0 0 2B no
Lung, lower lobe 17291 1, 3 F 53 Pleomorphic ca IV 3 0 nd 2B no
Tonsillar pillar 17307 2 M 67 SCC, NOS I 0 2B 1 4C no
Rectosigmoid junction 17346 3 M 57 Ad, NOS II 3 0 nd 2A no
Lung, lower lobe 17448 2, 3 M 71 Ad-SCC II 2 0 X 1B no
Colon, splenic flexure 17641 1, 2, 3 F 59 Ad, NOS II X X nd nd FOLFIRI & Avastin, Erbitux,
irinotecan then oxaliplatin &
Xeloda then SAHA, 5-FU and
leucovorin.
Cecum 17651 3 F 74 NE n.d. 4 1 X 4 no




18254 1, 2 F 69 Inf Duct, NOS III 3 1 X 2B no
Floor of mouth, NOS 18316 2 F 47 SCC, krt I X X nd nd Cisplatin and Taxotere
Duodenum 18484 2 M 77 Ad, NOS II 4 1 0 3 no
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Table 1 Clinical characteristics of tumors and experiments in which corresponding xenografts were used (Continued)
Pancreas, head of 18643 2 F 56 Inf Duct, NOS I 3 1 0 2B Chemoradiation: total of
5040 cGy with gemcitabine
Pancreas, overlapping
lesion
19632 2 F 78 Inf Duct, NOS III 3 0 nd 2A no
Palate, soft, NOS 19785 5 M 65 SCC, lg cell,
nonkrt
III 0 0 X nd Induction chemotherapy
For each tumor listed, the sex, age at first diagnosis, histological description, histological grade, pathological stage and treatment (if any) prior to specimen
acquisition is included. The ID# refers to the de-identified number given to the procured samples. Exp indicates the experiments for which the xenograft of each
tumor was used: 1- validation of antibody species-specificity, 2-localization of human mitochondria, 3- survey of time to first passage and species identification of
vasculature, 4- kinetics of vascularization of engrafted tumors and 5- the perfusion study. For histological descriptions, the following abbreviations are used: NOS-
not otherwise specified, Ad- adenocarcinoma, PSC- papillary serous cystadenocarcinoma, SSPC- serous surface papillary carcinoma, Meso- mesothelioma, biphasic,
malignant, Inf Duct- infiltrating ductal carcinoma, RCC- renal cell carcinoma, SCC- squamous cell carcinoma, CSC- combined small cell carcinoma, Ad-Sq-
adenosquamous, NE- neuroendocrine, krt- keratinizing. For histological grades the following definitions were used: Grade I: well differentiated, Grade II:
moderately differentiated, moderately well differentiated, intermediate differentiated, Grade III: poorly differentiated, Grade IV: undifferentiated, anaplastic.
Histological staging is per AJCC (American Joint Committee on Cancer), nd- no data.
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of a pancreatic tumor (Figure 1C) but not in a Colo205
xenograft (Figure 1D). Similarly, an anti-human CD31
antibody labeled vessels in a specimen of patient lung
tumor (Figure 1E) but not the Colo205 xenograft
(Figure 1F). Conversely, an antibody recognizing mouse
CD34 did not label the patient lung tumor specimen
(Figure 1G), but did label vessels in the Colo205 xeno-
graft (Figure 1H). Therefore, these antibodies were used
to identify the species of origin of the vessels in FFPE
archival specimens.
We carried out an initial characterization of this model
in 17 individual patient tumor/ 1st passage xenograft
pairs which included 8 different tumor types (3 colon, 2
lung, 3 pancreatic, 1 RCC, 2 head and neck, 1 duodenal,
2 ovarian and 3 esophageal tumors) using blocks of
engrafted tumors which had grown to approximately
1–1.5 cm3 (a size at which these tumors were reim-
planted to a second passage) from our FFPE archive of
xenografted tumors. Tumors were often found to have
scattered areas of central necrosis and so evaluation of
staining patterns was carried out on selected areas of
viable tumor. The antibody to the human mitochondrial
antigen was used to identify cells of patient (human)
origin and revealed that both tumor and stromal cells in
the sections of patient specimens were labeled (Figure 2A,
B, C, G, H). However, the only labeled cells in tumors
which had successfully engrafted in SCID mice were the
malignant tumor cells and, notably, stromal elements were
not similarly labeled (Figure 2D, E, F, J, K; data for ovarian
and esophageal tumors not shown). We also noticed that
while endothelial cells of apparent vessels in the patient
specimens were labeled by the anti-human mitochondrial
antibody, vessels in the xenografts were not. A preliminary
analysis of the vascular elements in a patient pancreatic
tumor and xenograft with anti-human CD34 antibody
confirmed the abundant presence of human vessels in the
original surgical specimen, but anti-human CD34 didnot label vessels in the xenograft (Figure 2I, L). These
observations strongly suggested that the growth of
successful xenografts was supported through the recruit-
ment of mouse stromal elements.
Successfully engrafted patient tumors are characterized
by the presence of mouse vasculature, but human vessels
are not detectable
It has been suggested that implanted tumors may vary in
the degree to which the original human vasculature
survives [22,23]. To specifically determine the origin of
vessels which support the growth of successfully en-
grafted patient xenografts, we compared the presence of
human and mouse blood vessels in surgical specimens
and tumors engrafted in SCID mice as above. We ran-
domly selected surgical specimens and corresponding
first passage xenografts of four different types of tumors:
colon, pancreatic, lung and renal cell carcinoma (3–7
different tumors in each panel). Serial sections of each
surgical specimen and the corresponding xenograft were
stained for either huCD31 or msCD34.
Patient xenografts of different tumor types selected for
this study grew at slightly different rates and there was
variability between tumors with regard to the time to
first passage. Colon tumors grew the most rapidly with a
mean growth time to passage of 15 weeks. In compari-
son, the other tumor types grew slightly more slowly.
The average time to resection of pancreatic, lung and
renal cell carcinomas was 20–25 weeks.
In each of the original patient tumor specimens
(Figure 3), huCD31(+) blood vessels were apparent
(Figure 3A, D, G, J). At the time of resection, huCD31(+)
vessels were not detectable (Figure 3B, E, H, K), however
msCD34(+) vessels were clearly apparent within the
stroma (Figure 3C, F, I, L). Additionally, quantification of
microvessel densities in these tumors confirms a prepon-







Figure 1 Antibodies selected for characterization of stromal cells and vasculature in FFPE specimens are species-specific. (A, B) Labeling
of a patient colon tumor (A) and Colo205 human cell line xenograft (B) with anti-human mitochondrial antibody (single arrow- tumor cells;
double arrows- stroma). (C, D) Labeling of a patient pancreatic tumor (C) and Colo205 human cell line xenograft (D) with anti-human CD34. (E, F)
Labeling of a patient lung tumor (E) and Colo205 xenograft (F) with anti-human CD31. (G, H) Labeling of a patient lung tumor (G) and Colo205
xenograft (H) with anti-mouse CD34. (bars = 50 μ).
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As discussed above, a survey of tumor types found that
by the time successfully engrafted tumors reached a size
large enough to be passaged, colon, pancreatic, lung and
renal cell tumors were vigorously vascularized by a
network of vessels of murine origin. To determine the
time-frame of vasculature development in xenografted
patient tumors, this process was analyzed using two
different patient tumor xenograft models, a mesotheli-
oma and a metastatic colon tumor, for which largeamounts of tumor tissue were available enabling the
engraftment of many mice with the same primary
tumor.
A specimen of mesothelioma was engrafted into 12
SCID mice which were then monitored until tumors
became palpable at 4 weeks post-implantation. Speci-
mens were then resected and prepared for histology at 4,
5, 6, 7 and 9 weeks post-implantation. This tumor grew
rapidly and a first passage tumor was recovered and





Figure 2 Stromal elements in patient derived xenografts at termination of the first passage in SCID mice did not label with an
anti-human markers; comparison of human markers in patient tumor specimens (A, B, C, G, H, I) and the first passage of the same
tumor established as a xenograft (D, E, F, J, K, L). The anti-human mitochondrial antibody labeled tumor (single arrow) and stromal cells
(double arrows) in patient specimens (A, B, C, G, H), but only tumor cells (single arrow) in the xenografts (D, E, F, J, K) while the stroma cells
(double arrows) were unstained. Similarly, an anti-human CD34 antibody labeled vessels (arrow) in a patient tumor (I) but not in the xenograft
(L). (A,D- Colon tumor; B, E- Lung tumor; C, F- Pancreatic tumor; G, J- RCC; H, K- Head & Neck tumor; I, L- Pancreatic tumor). (bars = 50 μ; except I,
L bars = 100 μ).
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resected and re- passaged a third time on day 108.
Samples of the original surgical specimen, first passage
and second passages were analyzed. The original patient
specimen showed widespread labeling of huCD31(+)
cells (Figure 5A) and no reactivity with msCD34
(Figure 5D). By 4 weeks, when measureable tumor
growth was first detected, there were still detectable
huCD31(+) vessels (Figure 5B) while mouse CD34(+)
blood vessels were also already abundant in the interior
of the xenografts (Figure 5E). At 9 weeks, very few
huCD31(+) vessels were detectable (Figure 5C) and the
great majority of labeled vessels were msCD34(+)
(Figure 5F). Where huCD31(+) blood vessels were seen,
they were fragmented and sparsely dispersed (not shown).
Blood vessels in established mesothelioma xenografts
transplanted into a second passage stained exclusively formsCD34 (data not shown). The number of huCD31(+) or
msCD34(+) vessels at each time-point was quantified by
counting the number of microvessels in five fields of view
at 20× and averaging (Figure 5G). At 4 weeks, the
mesothelioma xenograft had a huCD31(+) blood vessel
MVD of 15 and a msCD34(+) blood vessel MVD of 44.
Over the next five weeks, resected tumors showed dimi-
nished numbers of huCD31(+) vessels and the strong
presence of msCD34(+) vessels. We observed variability in
msCD34(+) MVD from a high at week 5 to an equilibrium
at weeks 7–9. This suggests an initial high number of
mouse vessels as the original implant is vascularized and
then a change in proportion of vessels to tumor cells as
proliferation of tumor cells increases.
To examine an engrafted tumor at earlier timepoints,
a specimen of a metastatic colon adenocarcinoma was





Figure 3 At the time of second passage, vessels in successfully growing xenografts of four different tumor types surveyed were of
murine origin: A-C Colon; D-F Lung; G-I Pancreatic; J-L Renal Cell Carcinoma. For each tumor type, a representative section of an original
patient specimen labeled with anti-huCD31 is shown (A, D, G, J). For each tumor, sections of the first passage xenografted tumor when it was
resected are also shown; while no huCD31(+) vessels were identified in the xenografts (B, E, H, K), msCD34(+) vessels were abundant (C, F, I, L).
(bars = 50 μ).
Hylander et al. Journal of Translational Medicine 2013, 11:110 Page 8 of 14
http://www.translational-medicine.com/content/11/1/110growth, colon xenografts were resected at 3 days and
one week followed by weekly intervals. As expected, the
original patient specimen stained strongly for huCD31
(Figure 6A) and did not stain for msCD34, (Figure 6D).
Tumors recovered at 3 days, one week and two weeks
were not larger than the original implanted piece, but
already showed greatly reduced labeling for huCD31 (see
graph Figure 6G). At these early times, although no
histological evidence of tumor glandular structures was
seen in sections from the implantation sites, msCD34(+)
vasculature was seen in the peripheral connective tissue
surrounding the implant. By 3 weeks post-implantation,
glandular structures were apparent in the periphery of
the sample signifying growth of the implanted tumor
and these glands were surrounded by vessels staining
strongly for msCD34, but huCD31(+) vessels were notdetectable. From 4–8 weeks post-implantation, as the tu-
mors grew and the malignant glandular structures
expanded, huCD31(+) vessels were not detectable
(Figure 6B,C), while an extensive network of msCD34(+)
vessels was apparent (Figure 6E,F). In summary, the
human vessels were rapidly lost in the early stages of
engraftment and vasculature derived from the mouse
predominated during the growth phase (Figure 6G).
Functional vasculature during growth of xenografts is of
mouse origin
In the slides of the mesothelioma and colon xenografts
described above, vessels of murine origin were often
seen to contain red blood cells (RBCs) supporting the
idea that these murine vessels were functional and














Figure 4 Successfully engrafted tumors which had grown to a size to be passaged were primarily vascularized by vessels derived from
the murine hosts. Comparison of the microvessel density (MVD) in the patient surgical specimens (ss) and engrafted tumors (-1p) showed that
most of the huCD31(+) vessels were lost during tumor growth in the mouse. At the time of first passage, few remaining remnants of huCD31(+)
cells were detectable and the major source of blood vessels was the recruitment of msCD34(+) vessels of murine origin. (Values shown are
averages of 5 fields/tumor counted at 20×).
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vessels were functional in growing xenografts, we engrafted
a cohort of mice with a head and neck tumor and tumor
growth was monitored. At intervals between 4 weeks to 8
weeks post-implantation, tumors were measured and mice
were injected systemically (by tail vein) with Dylight 594
labeled tomato lectin (red fluorescence) to visualize per-
fused vessels; tumors and intestinal tissue (as a control for
successful perfusion) were resected and embedded in
OCT. For this study, tumors were selected for analysis
based on growth (as indicated by volume) rather than time
after implantation. Analysis of tumors was initiated once
vigorous growth began; these tumors ranged in size from
32–75 mm3 on day 20 after implantation when palpable
tumors became apparent, to 200–800 mm3 after day 42.
Freshly obtained cryosections were prepared and perfused
vessels were visualized by fluorescence microscopy. Im-
munofluorescence staining was performed on frozen
sections using either anti-msCD31 or anti-huCD34 to
determine the origin of perfused vessels. We observed that,
as tumors grew, perfused vessels were clearly evident in
the connective tissue surrounding the tumor (Figure 7C-F).
At all stages of growth, these perfused vessels adjacent to
the tumor stained strongly for msCD31. Vessels positive
for msCD31were also visualized within the tumors
(Figure 7C-D, green arrows), while no vessels in these
tumors labeled for huCD34 (data not shown). Lectin
perfused vessels were sparse within tumors of all sizes, but
when detected, these were observed to co-stain for
msCD31 (Figure 7D-F, yellow arrows). These resultssuggest that even when abundant vessels are recruited, as
the tumor grows, well perfused vessels are mainly limited
to the periphery.
Overall, these results support the conclusion that
growth of patient xenografts in SCID mice is supported
by vasculature recruited from the murine host. Although
fragments of the vessels originally present in the human
tumor implant could sporadically be visualized, we
found no evidence that these residual fragments were
functional or sustained the actual growth phase of the
xenografts.
Discussion
Although there is general acceptance of the fact that
patient derived tumor xenografts provide a model in
which the histology and genetics of the original tumor is
maintained, there is not yet a clear understanding of the
actual process of engraftment and the fate of various
components of the patient tumors. For example, a recent
review discussing the benefits of the patient tumor xeno-
graft model for predicting drug responses states that
while cell line xenografts lack human stroma and im-
mune cells, in patient xenografts the tumor and stromal
components are from the same individual [25] although
these authors also state that this may vary depending on
the strain of mouse used. In a recent review, Tentler
[20] points out that the answer to the question of how
long the human vasculature and other components
survive in patient xenografts is controversial. Overall, in

















Figure 5 The growth of a patient mesothelioma xenograft was supported by development of a murine vascular network. A patient
mesothelioma was implanted in a cohort of mice and monitored for tumor growth. Once tumors began to actively grow, representative tumors
were resected at weekly intervals and analyzed for vessel content. Staining for huCD31 was prominent in the original patient specimen (A), much
reduced at 4 weeks (B) and negligible at 9 weeks (C). In contrast, patient specimens were not stained for msCD34 (D), whereas at 4 weeks large
numbers of vessels stained for msCD34 (E) and by 9 weeks, msCD34 labeled vessels were predominant (F). The graph (G) summarizes the loss of
detectable human vessels and acquisition of murine vessels over a 9 week period. (bars = 100 μ).
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therapeutics, it is critical to better understand this
process. Additionally, as patient xenografts are increas-
ingly used to study therapeutic efficacy, this could be
particularly important in therapeutic experiments in
which the vasculature or other stromal elements are be-
ing targeted.
For this study, we used representative first passage
xenografts of eight different tumor types. Our findings
presented here support the conclusion that, in patient
xenografts, the malignant cells in the patient tumor
survive while components of the original stroma do not.
In identifying the origin of the vasculature in a survey of
four different tumor types (pancreatic, lung, colon and
renal cell carcinoma) we found that the only vessels
detectable at the time of first passage were host-derived.
Our kinetic studies of two different tumors show that
although the time frame of host vessel recruitment maydiffer slightly between tumor types, as previously repor-
ted for RCC and colon tumors [22,23], ultimately the
human vessels were lost and tumor growth was
supported by host vessels. Also as seen previously, some
of these vessels contain RBCs attesting to their function-
ality, and we have confirmed this by dye perfusion
experiments. Thus the general consensus of the few
reports in which this question has been studied specif-
ically in patient tumor xenografts is that under expe-
rimental protocols in which undisrupted pieces of
patient tumors are directly engrafted into immuno-
deficient mice, the engraftment and growth of the
xenografts is largely supported by recruitment and
incorporation of host stromal elements, particularly the
vasculature.
There are cases where investigators would like to be
able to establish xenograft models with human stromal
















Figure 6 Vascularization of an engrafted patient colon tumor. A patient colon tumor was implanted in a cohort of mice and vessel
development was analyzed over 8 weeks. Vessels in the original patient specimen labeled strongly for huCD31 (A) and not for msCD34 (D).
Representative sections showing loss of huCD31(+) vessels (B- 4 weeks, C- 7 weeks) and presence of msCD34(+) vessels (E- 4 weeks, F- 7 weeks)
are shown. The graph (G) summarizes this process; huCD31(+) vessels were rapidly lost, and by one week, mouse vessels were the predominate
vessels present in the colon tumors (no data for msCD34 at 2 weeks; bars = 100 μ).
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engrafting pieces of human skin onto immunodeficient
mice. Using this approach, melanoma cell lines im-
planted in human skin grafts survived for several months
and human vessels were observed to anastomose with
host vessels and support tumor growth [26]. Similarly,
Tahtis et al. [27] successfully engrafted human skin onto
SCID mice and subsequently implanted MCF7 cells in
the xenografted skin. The tumors grew and developed
extensive stroma and vasculature of human origin which
remained viable as murine vessels grew into the tumor,
and both were identifiable at 10 weeks after engraftment,
although eventually murine vessels formed the majority
of the vasculature. Early attempts to engraft human skin
into nude mice also demonstrated that the human ves-
sels were gradually replaced by murine vessels [28]. This
type of SCID mouse/human skin model has been used
to study anti-angiogenic treatments in xenografted
breast cancer cell line models [29,30]. Human bonecontaining human blood vessels has also been xeno-
grafted in SCID mice and been shown to support tumor
formation by human prostate cancer cells, which do not
similarly colonize mouse bone [31].
Recently, a model of human angiogenesis within intact
pieces of prostate tumor has been developed to facilitate
study of anti-angiogenic therapy for prostate cancer
[22,32]. Prostate endothelial cells express androgen re-
ceptor and this model depends on the implantation of
slow release testosterone pellets prior to engraftment.
These authors demonstrate a burst of angiogenesis of
the endogenous human vessels during the first 14 days
after implantation that was significantly less in mice
without the testosterone pellets; this activity is prostate
specific and was not observed in RCC xenografts.
Between 15–30 days, this new vasculature matured,
becoming associated with pericytes and showed reduced
leakage. These authors point out, though, that this






Figure 7 Murine vessels were functional in xenografted tumors. (A, B) Paraffin sections of first passage xenografts of the mesothelioma (A)
and colon (B) tumors labeled for msCD34 show that murine vessels often contained red blood cells (arrows). (C-F) A patient head and neck
tumor was engrafted into a cohort of mice and the growth of xenografts was monitored beginning 19 days after implantation when tumors
became palpable. Functional analysis of vessels was carried out on tumors of different sizes. Animals were injected with Dylight-594 labeled
tomato lectin (red) and frozen sections were prepared. Representative sections stained for msCD31 visualized with a Dylite 488 (green) secondary
antibody are shown: volumes were (C) 19 mm3, (D) 75 mm3, (E) 190 mm3 and (F) 600 mm3. In each case, msCD31(+) vessels (green arrows)
were seen in the tumors, both centrally and in the periphery. Perfused vessels which were msCD31(+) were seen in the periphery of tumors
(D-F; yellow arrows). Non-perfused vessels were also observed in the central portions of these tumors. (bars = 100 μ).
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passaging, so that this model provides a window of
opportunity for observing stromal/tumor cell interac-
tions and performing pre-clinical therapeutic testing on
patient derived prostate tumors.
Conclusions
In summary, although there are some special situations
in which human tumor xenografts may be supplied, at
least for a while, with human derived vessels, we
observed overall that in the patient tumor xenograft
model in which intact tumor pieces are directly
engrafted into naive, unmanipulated SCID mice, vessels
of mouse origin can be detected in the periphery of the
tumor at very early stages of engraftment. These can beseen even while residual human vessels are still detect-
able. However, this situation rapidly changes as the num-
ber of viable murine vessels increases and the human
vessels become fragmented. We found no evidence to
suggest that human vessels contribute significantly to
the engraftment process in the models we examined.
Furthermore, we have never observed any human vessels
in subsequently passaged tumors. Because persistence of
human vessels seems to be an exception rather than the
rule, the characterization and timeframe of stromal and
vascular development should be validated for each indi-
vidual experimental tumor model. This is particularly
important when using these models for testing therap-
ies directed at stromal components and when such
models are being used for genetic analyses.
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